Osteopathic medicine in Canada

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

Retrieved on: 
Wednesday, March 6, 2024
Type 2 diabetes, Week, PD, Treatment, Cancer, Food, GLP1, Conference, ATTD, Biomarker, Hypoglycemia, DSM-IV codes, Area studies, Poster, C-peptide, Osteopathic medicine in Canada, Pharmaceutical industry

REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced three poster presentations presenting long-term 26 week follow-up data from patients treated with BMF-219, enrolled in the escalation portion of the ongoing Phase II clinical study (COVALENT-111), at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place in Florence, Italy from March 6-9, 2024. This clinical data from all dosing cohorts initiated to date as of February 12, 2024 from the Escalation Phase of COVALENT-111 will be featured during a Poster Discussion Presentation and two Poster Viewing Presentations at ATTD. Biomea will showcase the following three e-poster presentations:

Key Points: 
  • Please find a link here to our website where the poster presentations and discussion will be available.
  • A higher proportion of patients treated with 200mg QD achieved a clinically significant reduction in HbA1c compared to 100mg QD dosing.
  • A durable glycemic response (≥1.0% HbA1C reduction) was seen in 20% and 36% of patients in once daily 100 mg and 200 mg cohorts, respectively.
  • A PK study further assessing the optimal use of BMF-219 to ensure minimal variability of exposure is currently under way.

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 9, 2024
Diabetes, DSM-IV codes, Patient, Leukemia, CTA, PST, Research, CLL, Osteopathic medicine in Canada, Diagnosis, FLT3, NSCLC, Insulin, Cancer, IND, Conference, Safety, DLBCL, FDA, Glycated hemoglobin, PDAC, AML, CRC, Phase, Health Canada, Week, Pharmaceutical industry

Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024.

Key Points: 
  • Open label portion of Phase II COVALENT-112 study readout in 40 patients with type 1 diabetes expected in 2024.
  • A live webcast of the presentation will be available on the Investors & Media page of Biomea’s website at: https://investors.biomeafusion.com/news-events/events .
  • “2023 was a truly remarkable year for Biomea as we had several positive data readouts in both type 2 diabetes and AML.
  • “We believe BMF-219 has the potential to address the root cause of diabetes and modify its progression in patients.

The Inner Circle Acknowledges, Allan Lamb as a Pinnacle Platinum Healthcare Professional

Retrieved on: 
Friday, December 29, 2023
Liver, General surgery, Inner circle, American Osteopathic Association, University college, State, FACS, Stomach, Physician, Multimedia, Bile, Pancreas, Osteopathic medicine in Canada, Education, Advisory Committee, Earlham College, Appendix, Nursing, Professional, Esophagus, American College, Des Moines University, Committee, Patient, Thyroid, Henry Ford Health, Dentistry

TRENTON, Mich., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Allan Lamb is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the fields of General Surgery and Osteopathic Medicine.

Key Points: 
  • TRENTON, Mich., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Allan Lamb is acknowledged as a Pinnacle Platinum Healthcare Professional for his contributions to the fields of General Surgery and Osteopathic Medicine.
  • Dr. Lamb pursued higher education at Earlham College in 1989 where he earned a Bachelor of Arts degree.
  • He then attended Des Moines University College of Osteopathic Medicine in 1995 and received a Doctor of Osteopathic Medicine degree.
  • Dr. Lamb currently serves as an osteopathic physician and the President of Lakeshore Surgical Consultants PLC in Trenton, Michigan.

Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH

Retrieved on: 
Monday, December 11, 2023
CRS, CYP, NPM1, Hematopoietic stem cell transplantation, Level 4, Arm, MEN1, ITGAM, Plasma, MEIS1, Society, DS, Hydroxycarbamide, ASH, Postcholecystectomy syndrome, Mutation, Steroid, DSM-IV codes, ANPEP, Gene expression, CD14, Cancer, Poster, Toxicity, HSCT, Patient, AUC, AML, Osteopathic medicine in Canada, Pharmaceutical industry

Pharmacodynamic data from a case study of an AML patient containing NUP98-NSD1 mutation showed suppression of key leukemogenic genes (e.g.

Key Points: 
  • Pharmacodynamic data from a case study of an AML patient containing NUP98-NSD1 mutation showed suppression of key leukemogenic genes (e.g.
  • Initially, patients were enrolled agnostic to mutational status; subsequently, the study protocol was amended to enrich for patients with AML harboring menin-dependent mutations.
  • Biomea is planning to amend the dosing protocol to explore higher dosing levels in Arm B.
  • Dose escalation is to be followed by a dose optimization/expansion to determine the recommended phase 2 dose.

Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

Retrieved on: 
Saturday, December 9, 2023
Phase, Flexner Report, Diabetes, Conference, BID, QD, Menin, ATTD, Animal, Week, DSM-IV codes, Cancer, Food, SAD, Gene, Patient, Diagnosis, Safety, Harvard Medical School, Joslin Diabetes Center, Osteopathic medicine in Canada, Kinetics, Pharmaceutical industry

At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%.

Key Points: 
  • At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%.
  • As presented at the conference, we have shown for the first time the long-term follow-up data of our 100 mg patient cohorts.
  • By increasing the dose from 100 mg to 200 mg, we are excited about nearly doubling the percentage of patients treated with BMF-219 having a robust HbA1c reduction of 1% or more, 22 weeks after the last dose.
  • Phase II consists of multiple ascending dose (MAD) cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.

AACOM Announces 2023 Arnstein Minority Student Scholarship Recipients

Retrieved on: 
Thursday, December 7, 2023
Physician, Student, Male, Housing, Osteopathy, Hospital, Education, Osteopathic medicine in Canada, Patient, Medicine, Arnstein, Sherry, AACOM, Nursing

Bethesda, MD, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Recognizing the achievements and passion of six inspiring student doctors, the American Association of Colleges of Osteopathic Medicine (AACOM) today announced the recipients of the 2023 Sherry R. Arnstein Underrepresented Minority Scholarship.

Key Points: 
  • Bethesda, MD, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Recognizing the achievements and passion of six inspiring student doctors, the American Association of Colleges of Osteopathic Medicine (AACOM) today announced the recipients of the 2023 Sherry R. Arnstein Underrepresented Minority Scholarship.
  • There is no better way to honor the legacy of Sherry Arnstein.”
    The Sherry R. Arnstein Underrepresented Minority Student Scholarship was established in honor of Arnstein’s lifelong dedication to public service, social equity and justice.
  • “I am incredibly honored to have been chosen as a 2023 AACOM Sherry R. Arnstein Underrepresented Minority Scholarship recipient,” said Carley Andrew.
  • I hope to someday continue Ms. Arnstein’s legacy of dedication to public service, social equity, and justice.”
    “I would like to thank AACOM for awarding me the 2023 Arnstein Scholarship.

Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

Retrieved on: 
Tuesday, December 5, 2023
T1D, FDA, Person, Health, Diabetes, Insulin, MD, DSM-IV codes, Type 2 diabetes, Cancer, Health Canada, Patient, Diagnosis, Safety, Osteopathic medicine in Canada, CTA, Pharmaceutical industry

REDWOOD CITY, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Health Canada has cleared Biomea's Clinical Trial Application (CTA) to study BMF-219 in adults living with type 1 diabetes.

Key Points: 
  • Beta cell loss is a root cause of type 1 and type 2 diabetes.
  • Preclinical studies have shown the potential of BMF-219 to specifically regenerate and retain insulin-producing beta cells in animal models of type 1 and type 2 diabetes.
  • The trial will also include an open label portion for adults with type 1 diabetes up to 15 years since diagnosis.
  • “Our study COVALENT-111 is currently enrolling persons with type 2 diabetes and has generated tremendous enthusiasm among investigators in Canada.

Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024

Retrieved on: 
Monday, November 27, 2023
Phase, Conference, Dose, ATTD, Type 2 diabetes, Week, Abstract, DSM-IV codes, Cancer, Treatment, Poster, Safety, Osteopathic medicine in Canada, Pharmaceutical industry

These abstracts further validate the mechanism of action of covalently inhibiting menin in people with type 2 diabetes to potentially provide long-term improvement in glycemic control through beta cell regeneration.

Key Points: 
  • These abstracts further validate the mechanism of action of covalently inhibiting menin in people with type 2 diabetes to potentially provide long-term improvement in glycemic control through beta cell regeneration.
  • Biomea will disclose additional information about the presentations in accordance with the ATTD abstract embargo policies.
  • Phase II consists of multiple ascending dose cohorts and dose durations and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.

Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023: A New Generation of Proteins that have Found Application as a Therapeutic Target in Several Prevalent Diseases - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 21, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, MLL, Marketing, NPM1, Lung cancer, Protein, Indication, Acute lymphoblastic leukemia, MEN1, KMT2A, Research, FDA, EMA, Colorectal cancer, Leukemia, MYC, Diabetes, Menin, Clinical trial, Cancer, Mutation, Pancreatic cancer, Bone marrow, Patient, Acute myeloid leukemia, ALL, Acute leukemia, AML, Osteopathic medicine in Canada, Fast Track, Pharmaceutical industry

The "Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • Menin represents a new generation of proteins that have found application as a therapeutic target in several prevalent diseases, especially cancer.
  • This has generated the need for development of menin inhibitors that can be used to treat these diseases.
  • Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023 Report Highlights:
    Menin Inhibitors Drugs In Clinical Trials: > 10 Drugs
    Global Menin Inhibitors Drugs Clinical Trials By Company, Indication & Phase
    Menin Inhibitors Clinical Research Innovation Trends By Region: US, Europe & Canada

Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease

Retrieved on: 
Thursday, November 16, 2023
Safety, PST, Food, Diabetes, Patient, DSM-IV codes, BID, Osteopathic medicine in Canada, Phase, Insulin resistance, Cancer, Pharmaceutical industry

The abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" was selected as one of six oral presentations by the WCIRDC Abstract Committee.

Key Points: 
  • The abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" was selected as one of six oral presentations by the WCIRDC Abstract Committee.
  • In the completed Phase I portion of the trial, healthy subjects were enrolled in single ascending dose cohorts to ensure safety at the prospective dosing levels for people with type 2 diabetes.
  • Phase II consists of multiple ascending dose cohorts and dose durations and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT05731544.